Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

October 01, 1994; Volume 46,Issue 4
  • You have access
    Omega-agatoxin-TK containing D-serine at position 46, but not synthetic omega-[L-Ser46]agatoxin-TK, exerts blockade of P-type calcium channels in cerebellar Purkinje neurons.
    M Kuwada, T Teramoto, K Y Kumagaye, K Nakajima, T Watanabe, T Kawai, Y Kawakami, T Niidome, K Sawada and Y Nishizawa
    Molecular Pharmacology October 1994, 46 (4) 587-593;
  • You have access
    Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
    S M De Morais, G R Wilkinson, J Blaisdell, U A Meyer, K Nakamura and J A Goldstein
    Molecular Pharmacology October 1994, 46 (4) 594-598;
  • You have access
    Gold sodium thiomalate down-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on vascular endothelial cells.
    R Koike, I Miki, M Otoshi, T Totsuka, H Inoue, H Kase, I Saito and N Miyasaka
    Molecular Pharmacology October 1994, 46 (4) 599-604;
  • You have access
    Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
    M K Ritke, J M Rusnak, J S Lazo, W P Allan, C Dive, S Heer and J C Yalowich
    Molecular Pharmacology October 1994, 46 (4) 605-611;
  • You have access
    Induction of aggregation and augmentation of protein kinase-mediated phosphorylation of purified vimentin intermediate filaments by withangulatin A.
    M D Perng, T J Cheng, C M Chen and Y K Lai
    Molecular Pharmacology October 1994, 46 (4) 612-617;
  • You have access
    Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator.
    N G Hord and G H Perdew
    Molecular Pharmacology October 1994, 46 (4) 618-626;
  • You have access
    Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
    J S Lee, K Paull, M Alvarez, C Hose, A Monks, M Grever, A T Fojo and S E Bates
    Molecular Pharmacology October 1994, 46 (4) 627-638;
  • You have access
    Time course of 72-kilodalton heat shock protein induction and appearance of trifluoroacetyl adducts in livers of halothane-exposed rats.
    W Q Lin, R A van Dyke, H M Marsh and J R Trudell
    Molecular Pharmacology October 1994, 46 (4) 639-643;
  • You have access
    Kinetics and reversibility of thyrotropin-releasing hormone-stimulated guanine nucleotide exchange in membranes from GH4C1 cells.
    K D Brady, B Han and A H Tashjian
    Molecular Pharmacology October 1994, 46 (4) 644-652;
  • You have access
    Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression.
    G Nickenig and T J Murphy
    Molecular Pharmacology October 1994, 46 (4) 653-659;
  • You have access
    L-type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines.
    R Bangalore, N Baindur, A Rutledge, D J Triggle and R S Kass
    Molecular Pharmacology October 1994, 46 (4) 660-666;
  • You have access
    Cocaine differentially regulates activator protein-1 mRNA levels and DNA-binding complexes in the rat striatum and cerebellum.
    P Couceyro, K M Pollock, K Drews and J Douglass
    Molecular Pharmacology October 1994, 46 (4) 667-676;
  • You have access
    Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.
    M N Benchekroun, E Schneider, A R Safa, A J Townsend and B K Sinha
    Molecular Pharmacology October 1994, 46 (4) 677-684;
  • You have access
    Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors.
    M Waelbroeck
    Molecular Pharmacology October 1994, 46 (4) 685-692;
  • You have access
    Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor.
    S Nouet, P Dodey, P Renaut, J Marie, D Pruneau, R Larguier, C Lombard and J C Bonnafous
    Molecular Pharmacology October 1994, 46 (4) 693-701;
  • You have access
    Membrane-permeant derivatives of cyclic AMP optimized for high potency, prolonged activity, or rapid reversibility.
    C Schultz, M Vajanaphanich, H G Genieser, B Jastorff, K E Barrett and R Y Tsien
    Molecular Pharmacology October 1994, 46 (4) 702-708;
  • You have access
    Biological studies of a nitroso compound that releases nitric oxide upon illumination.
    S J Pou, D E Anderson, W Surichamorn, L L Keaton and M L Tod
    Molecular Pharmacology October 1994, 46 (4) 709-715;
  • You have access
    Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons.
    C C Kuo and B P Bean
    Molecular Pharmacology October 1994, 46 (4) 716-725;
  • You have access
    Radiation inactivation studies of the dopamine reuptake transporter protein.
    S P Berger, K Farrell, D Conant, E S Kempner and S M Paul
    Molecular Pharmacology October 1994, 46 (4) 726-731;
  • You have access
    Biguanide derivatives: agonist pharmacology at 5-hydroxytryptamine type 3 receptors in vitro.
    P Morain, C Abraham, B Portevin and G De Nanteuil
    Molecular Pharmacology October 1994, 46 (4) 732-742;
  • You have access
    Identical inhibitory modulation of A-type potassium currents by dihydropyridine calcium channel agonists and antagonists.
    B Mlinar and J J Enyeart
    Molecular Pharmacology October 1994, 46 (4) 743-749;
  • You have access
    Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes.
    A E Busch, T Herzer, C A Wagner, F Schmidt, G Raber, S Waldegger and F Lang
    Molecular Pharmacology October 1994, 46 (4) 750-753;
  • You have access
    ATP-sensitive K+ channels of skeletal muscle fibers from young adult and aged rats: possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties.
    D Tricarico and D C Camerino
    Molecular Pharmacology October 1994, 46 (4) 754-761;
  • You have access
    Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes.
    R Gáspár, G Panyi, D L Ypey, Z Krasznai, G Vereb, C Pieri and S Damjanovich
    Molecular Pharmacology October 1994, 46 (4) 762-766;
  • You have access
    Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
    W Y Gao, D G Johns and H Mitsuya
    Molecular Pharmacology October 1994, 46 (4) 767-772;
  • You have access
    Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    J L Nitiss, P M Vilalta, H Wu and J McMahon
    Molecular Pharmacology October 1994, 46 (4) 773-777;
  • You have access
    Involvement of phenyl radicals in iodonium inhibition of flavoenzymes.
    V B O'Donnell, G C Smith and O T Jones
    Molecular Pharmacology October 1994, 46 (4) 778-785;
  • You have access
    Ethanol-derived immunoreactive species formed by free radical mechanisms.
    C Moncada, V Torres, G Varghese, E Albano and Y Israel
    Molecular Pharmacology October 1994, 46 (4) 786-791;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 46, Issue 4
1 Oct 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics